Jubilant Life gets US FDA nod for heart drug

ep-jubilantlife-usfda-600

The drug helps reduce the risk of recurrent nonfatal myocardial infarction (heart attack) in patients with a history heart disease and hyperlipidemia

Jubilant Life Sciences has received the final approval from US FDA for its generic Niacin extended-release tablets used for controlling cholesterol levels. The approval granted by the US Food and Drug Administration (US FDA) to the company’s wholly-owned arm Jubilant Pharma, is for multiple strengths of Niacin extended-release tablets of 500 mg, 750 mg, and 1,000 mg, the company said in a statement. These are the generic equivalent of AbbVie’s Niaspan, which is indicated to reduce elevated high-density lipoprotein (known as bad cholesterol), among others while increasing HDL-C (good cholesterol) in patients with primary hyperlipidemia and mixed dyslipidemia.

The drug helps reduce the risk of recurrent nonfatal myocardial infarction (heart attack) in patients with a history heart disease and hyperlipidemia, the statement added. “This is the first approval that we have received from the US FDA during the current financial year,” it said. As on March 31, 2018, Jubilant had a total of 94 ANDAs for oral solids filed in the US, the company said.